Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head
Executive Summary
Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.
You may also be interested in...
Novartis Counting On Depth Of Insight To Continue Success In Oncology
Its cancer pipeline planned with combinations in mind, the world’s second largest oncology company is positioned to ride the crest of the new wave in cancer drug development. Novartis is also paving new ground with quality of life research, an area of growing importance for oncology.
With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has
With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has